Efficacy of atorvastatin in achieving national cholesterol education program iow-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The women's atorvastatin trial on cholesterol (WATCH)

American Heart Journal

Volumn 141, Issue 6, 2001, Pages 949-956

  McPherson, Ruth ^a   Angus, Carmella ^b   Murray, Peter ^b   Genest Jr , Jacques ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b Parke Davis Canada   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035371373     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.115588     Document Type: Article

References (22)

1. Kannel WB. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham study. Am Heart J 1987;144:413-9.
2. Fetters JK, Peterson ED, Shaw L, et al. Sex-specific differences in coronary artery disease risk factors, evaluation and treatment: Have they been adequately evaluated? Am Heart J 1996;13:796-813.
3. Mosca L, Manson JA, Sutherland SE, et al. Cardiovascular disease in women. A statement for healthcare professional from the American heart association. Circulation 1997;96:2468-82.
4. Sacks FM, Maoye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446-52.
5. Longterm Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular disease and death with pravastatin in patients with coronary disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-54.
6. Kennedy JW, Kaiser GC, Fisher LD, et al. Clinical and angiographic predictors of operative mortality from the collaborative study in coronary artery surgery (CASS). Circulation 1991;63:793-802.
7. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998;97:1453-60.
8. Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and treatment of high blood cholesterol in adults (adult treatment panel). JAMA 1993;269:3015-23.
9. Schrott HL, Bittner V, Vittinghoff E, et al. Adherence to national cholesterol education program goals in postmenopausal women with coronary heart disease: The heart and estrogen/progestin replacement study (HERS). JAMA 1997;277:1281-6.
10. Davidson M, McKenny J, Stein E, et al. Comparison of one-year safety and efficacy of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin study group I. Am J Cardiol 1997;79:1475-81.
11. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women: The Framingham offspring study. Arterioscler Thromb Vasc Biol 1996;16:1509-15.
12. Despres JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arteriosclerosis 1990;10:497-511.
13. Lipid Research Clinics Program. Manual of Laboratory Operations. Bethesda (MD): National Institutes of Health; 1974.
14. Converse CA, Skinner ER. Lipoprotein Analysis: A Practical Approach. New York: IRL Press at Oxford University Press; 1992.
15. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of the low density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem 1972;18:499-502.
16. Lehmann EI. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day; 1975.
17. Winer BJ, Brown DR, Michels KM. Statistical Methods in Medical Research. 2nd Ed. New York: McGraw-Hill; 1991.
18. Lipid Research Clinics Epidemiology Committee. Plasma lipid distribution in selected North American populations: The lipid research clinics program prevalence study. Circulation 1979;60:427-39.
19. Brown AS, Bakker-Arkema, YeLLin L, et al. Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-72.
20. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL-cholesterol concentrations with atorvastatin, fluvastatin, lovastatin or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56.
21. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: Predicting risk by levels and ratios. Ann Intern Med 1994;121:641-7.
22. Auerbach BJ, Krause BR, Bisgaier CL, et al. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the caseinfed rabbit: Atorvastatin versus lovastatin. Atherosclerosis 1995;117:173-80.